Diretrizes brasileira para o manejo da asma

Diretrizes brasileira para o manejo da asma

(Parte 7 de 8)

Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lazarus SC, Lemanske RF Jr, Mauger E, Peters SP, Sorkness CA; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002; 109(3):410-8. 27. Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser

HB, Amin D, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005;94(4):465-72. 28. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K,

Ellsworth A, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol. 2005;95(1):6-71. 29. Zimmerman B, D’Urzo A, Berube D. Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol. 2004;37(2):122-7. 30. Bisgaard H. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature. Pediatr Pulmonol. 2000;29(3):221-34. 31. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36(5):391-8. 32. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC,

Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, Szefler SJ; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285(20):2594-603. 3. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF

Jr, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Long-acting beta2-agonist monotherapy vs continued therapy with inha-

IV Diretrizes Brasileiras para o Manejo da Asma S 471

J Bras Pneumol. 2006;32(Supl 7):S 447-S 474 led corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285(20):2583-93. 34. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320(7246):1368-73. 35. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153(5):1481-8. 36. Bateman ED, Boushey HA, Bousquet J, Busse W, Clark TJ,

Pauwels RA, Pedersen SE; GOAL Investigators Group.Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-4. 37. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J,

Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003;123(5):1480-7. 38. Kips JC, O’Connor BJ, Inman MD, Svensson K, Pauwels

RA, O’Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med. 2000;161(3 Pt 1):996-1001. 39. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM;

SMART Study Group.The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26. Erratum in: Chest. 2006;129(5):1393. 40. Barnes N, Thomas M, Price D, Tate H. The National montelukast survey. J Allergy Clin Immunol. 2005;115(1):47-54. 41. Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest. 2005;128(4):2954-62. 42. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J.

Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 1994;343(8904):1006-8. Erratum in: Lancet. 1994;343(8911):1512. 43. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF,

Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med. 1995;151(6):1907-14. 4. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ,

Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high- dose inhaled budesonide for moderate asthma. N Engl J Méd. 1997; 337(20):1412-8. 45. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet

J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma whoa are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-16. 46. Walker S, Monteil M, Phelan K, Lasserson T, Walters E Anti-

IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;(2):CD003559. 47. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H.

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378-86. 48. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumabi n allergic disease: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408-16. 49. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182-8. 50. Kuusela AL, Marenk M, Sandahl G, Sanderud J, Nikolajev

K, Persson B. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. Bambuterol Multicentre Study Group. Pediatr Pulmonol. 2000;29(3):194-201. 51. Zarkovic JP, Marenk M, Valovirta E, Kuusela AL, Sandahl G,

Persson B, et al. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. The Bambuterol Multicentre Study Group. Pediatr Pulmonol. 2000;29(6):424-9. 52. Szefler SJ, Nelson HS. Alternative agents for anti-inflammatory treatment of asthma. J Allergy Clin Immunol. 1998;102(4 Pt 2):S23-35. 53. Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van Der

Wouden JC. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax. 2000;5(1):913-20. 54. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999;54(10):1022-41. 5. Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma : systematic review of randomized-clinical trials using the Cochrane collaboration method. Allergy. 2006;61(10):1162-72. 56. Dinh Xuan AT, Lebeau C, Roche R, Ferriere A, Chaussain M.

Inhaled terbutaline administered via a spacer fully prevents exercise- induced asthma in young asthmatic subjects: a double-blind, randomized, placebo-controlled study. J Int Med Res. 1989;17(6):506-13. 57. Bengtsson B, Fagerstrom PO. Extrapulmonary effects of terbutaline during prolonged administration. Clin Pharmacol Ther. 1982;31(6):726-32. 58. McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst Rev 2003;(3): CD003535. 59. Ellman MS, Viscoli CM, Sears MR, Taylor DR, Beckett WS,

Horwitz RI. A new index of prognostic severity for chronic asthma. Chest. 1997; 112(3):582-90. 60. Morris N, Abramson MJ, Rosier MJ, Strasser RP. Assessment of the severity of asthma in a family practice. J Asthma. 1996;3(6):425-39. 61. Wahlgren DR, Hovell MF, Matt GE, Meltzer SB, Zakarian JM,

Meltzer EO. Toward a simplified measure of asthma severity for applied research. J Asthma. 1997;34(4):291-303. 62. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald

M. Risk factors for near-fatal asthma. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1804-9. 63. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults. A review. Chest. 2004;125(3):1081-102. 64. Idris AH, McDermott MF, Raucci JC, Morrabel A, McGorray

S, Hendeles L. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest. 1993;103(3):665-72. 65. Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma. An evidence-based evaluation. Chest. 2002;121(6):1977-87. 6. Browne G, Lam L. Single dose intravenous salbutamol bolus for managing children with severe acute asthma in the emergency department: re-analysis of data. Ped Crit Care Med. 2002;3(2):117-23. 67. Gluckman TJ, Corbridge T. Management of respiratory failure in patients with asthma. Curr Opin Pulm Med. 2000;6(1):79-85.

J Bras Pneumol. 2006;32(Supl 7):S 447-S 474

68. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW.

Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2000;(2):CD002178. Update in: Cochrane Database Syst Rev. 2001;(1):CD002178. 69. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. 2000;(2):CD001740. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001740. 70. Ratto D, Alfaro C, Sipsey J, Glovsky M, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA. 1988;260(4):527-9. 71. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. The effectiveness of inhaled corticosteroids in the emergency department treatment of acute asthma: a meta-analysis. Ann Emerg Med. 2002;40(2):145-54. 72. Rodrigo C, Rodrigo G. Treatment of acute asthma lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. Chest. 1994;106(4):1071-6. 73. Hart SP. Should aminophylline be abandoned in the treatment of acute asthma in adults? QJM. 2000;93(1):761-5. 74. Yung M, South M. Randomisedd controlled trial of aminophyline for severe acute asthma. Arch Dis Child. 1998;79(5):405-10. 75. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Database Syst Rev. 2000;(4):CD002742. 76. Silverman RA, Osborn H, Runge J, Gallagher EJ, Chiang W,

Feldman J, Gaeta T, Freeman K, Levin B, Mancherje N, Scharf S; Acute Asthma/Magnesium Study Group. IV Magnesium sulfate in the treatment of acute severe asthma. A Multicenter Randomized Controlled Trial. Chest. 2002;122(2):489-97. Erratum in: Chest. 2002;122(5):1870. 7. Scarfone RJ, Loiselle JM, Joffe MD, Mull C, Stiller S,

Thompson K, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med. 2000;36(6):572-8. 78. Cheuk DKL, Chau TCH, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child. 2005;90(1): 74-7. 79. Jones AM, Munavvar M, Vail A, Aldridge RE, Hopkinson L,

Rayner C, et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med. 2002;96(1):950–4. 80. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW.

Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2001;(1): CD000195. 81. Langton Hewer S, Hobbs J, Reid F, Lenney W. Prednisolone in acute childhood asthma: clinical responses to three dosages. Respir Med. 1998;92(3):541-6. 82. Scarfone RJ, Capraro GA, Zorc J, Zhao H. Demonstrated use of metered-dose inhalers and peak flow meters by children and adolescents with asthma exacerbations. Arch Pediatr Adolesc Med. 2002;156(4):378-83. 83. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M,

Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;(1):CD))1117. 84. Vilar EB, Reddy B, Silverman B, Rao YA, Chiaramonte L, Schneider AT. Superior clinical outcomes of inner city asthma patients treated in an allergy clinic. Ann Allergy Asthma Immunol. 2000;84(3):299-303. 85. Marguet C, Couderc L, Le Roux P, Jeannot E, Lefay V,

Mallet E. Inhalation treatment: errors in application and difficulties in acceptance of devices are frequent in wheezy infants and young children. Pediatr Allergy Immunol. 2001;12(4):224-30. 86. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12(5):1209-18. 87. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162(6):2341- 51. 8. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes

P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficulty/Therapy- Resistant Asthma. European Respiratory Society.. Eur Respir J. 1999;13(5):1198- 208. 89. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med. 2004;10(1):4- 50. 90. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker

ER, Postma DS. RiskfactorsassociatedwiththepresenceRisk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58(4):322-7. 91. Alvarez G, Schulzer M, Fitzgerald JM. AsystemicreviewofA systemic review of risk factors associated with near-fatal and fatal asthma. Can Respir J. 2005;12(5):265-70. 92. Rodrigo GJ, Rodrigo C, Nannini LJ. [Fatal or near-fatal asthma: clinical entity or incorrect management?] Arch Bronconeumol. 2004;40(1):24-3. Spanish. 93. Ayres KG, Miles JF, Barnes PJ. Brittle asthma. Thorax. 1998;53(4):315- 21. 94. Martinez-Moragon E, Plaza V, Serrano J, Picado C, Galdiz

JB, Lopez-Vina A et al. Near-fatal asthma related to menstruation. J Allergy Clin Immmunol. 2004;113(2):242- 4. 95. Mascia K, Haselkorn T, Deniz JM, Miller DP, Bleecker ER,

Borish L; TENOR Study Group. Aspirinsensitivityandseve-Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to treat asthma. J Allergy Clin Immunol. 2005;116(5):970- 5. 96. Serra-Battles J, Plaza V, Morejon PJ, Comella A, Brugues

J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322- 26. 97. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes

PJ, Chung KF; Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treatment asthma. Eur Respir J. 2003;2(3):478- 83. 98. Vonk. JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker

ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58(4):322- 7. 9. Irwin RS, Curley FJ, French CL. Difficult to control asthma: contributing factors and outcome of a systemic management protocol. Chest.1993;103(6):1662-9.Chest. 1993;103(6):1662- 9. 100. ten Brinke A, Ouwerkerk MA, Zwinderman AH, Zwinderman

(Parte 7 de 8)

Comentários